Invikafusp Achieves 59.3% Disease Control in Advanced Solid Tumor Trial
Early-phase clinical trials showed the novel dual T-cell agonist invikafusp was well-tolerated and achieved a 59.3% disease control rate in ...
Early-phase clinical trials showed the novel dual T-cell agonist invikafusp was well-tolerated and achieved a 59.3% disease control rate in ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.